Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome
Authors:
Open Access
- 29 April 2023
- journal article
- research article
- Published by Elsevier in Kidney International Reports
- Vol. 8 (7) , 1332-1341
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharmaceuticals UK Limited
- Novartis Pharma AG
- Novartis (GPP 2022)
This publication has 41 references indexed in Scilit:
- An international consensus approach to the management of atypical hemolytic uremic syndrome in childrenPediatric Nephrology, 2015
- Atypical Hemolytic Uremic SyndromeSeminars in Nephrology, 2013
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Genetics and Outcome of Atypical Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2013
- Recessive mutations in DGKE cause atypical hemolytic-uremic syndromeNature Genetics, 2013
- Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic SyndromeAmerican Journal of Transplantation, 2013
- The Development of Atypical Hemolytic Uremic Syndrome Depends on Complement C5Journal of the American Society of Nephrology, 2011
- Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical PhenotypeClinical Journal of the American Society of Nephrology, 2010
- Transplantation in Atypical Hemolytic Uremic SyndromeSeminars in Thrombosis and Hemostasis, 2010
- Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuriaBlood, 2005